Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088979 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Phase 2 study of Thyroid Eye Disease, sponsored by Tourmaline Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 20
- Study locations
NCT06088979: Recruiting Phase 2 study of Thyroid Eye Disease, sponsored by Tourmaline Bio.
NCT06088979 is a Phase 2 study of Thyroid Eye Disease that is actively recruiting participants, run by Tourmaline Bio. The registered enrollment target is 81 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06088979, a Phase 2 study of Thyroid Eye Disease, is actively recruiting participants, sponsored by Tourmaline Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TOUR006 - 20 MG
- DRUG TOUR006 - 50 MG
Study Locations (20)
California
- Headlands Research - AMCR - Site 840-131 - Escondido
- Foothill Eye Institute - Site 840-116 - Pasadena
- University of California Davis Eye Center - Site 840-119 - Sacramento
- Cockerham Eye Consultants - Site 840-114 - San Diego
- The Pacific Center for Oculofacial and Aesthetic Plastic Surgery - Site 840-122 - San Francisco
Florida
- Bascom Palmer Eye Institute - Site 840-115 - Miami
- Cordova Research Institute - Site 840-103 - Miami
- Aran Eye Associate - Sweetwater
Michigan
- W.K. Kellogg Eye Center - Site 840-126 - Ann Arbor
- Michigan State University - Site 840-127 - East Lansing
- Kahana Oculoplastic and Orbital Surgery - Site 840-112 - Livonia
Arizona
- Catalina Eye Care - Site 840-121 - Tucson
Colorado
- UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 - Aurora
Kentucky
- University of Louisville Health Eye Institute - Site 840-108 - Louisville
Massachusetts
- Ophthalmic Consultants of Boston - Site 840-128 - Boston
Minnesota
- Mayo Clinic - Site 840-102 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06088979 shows while recruiting
NCT06088979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06088979 names 20 study sites across 12 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06088979 about?
NCT06088979 is a clinical study titled "A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease". Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
What is the current status of trial NCT06088979?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2024-02-19. Estimated completion is 2027-09.
What conditions does trial NCT06088979 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06088979?
The interventions under investigation include: Placebo (OTHER), TOUR006 - 20 MG (DRUG), TOUR006 - 50 MG (DRUG).
Who is sponsoring clinical trial NCT06088979?
This trial is sponsored by Tourmaline Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088979 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06088979's enrollment target sits among peer trials
81 13th of 15 higher than 3 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
Anti-VEGF Therapy for Acute Thyroid Eye Disease
COMPLETED · Phase 2
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI